Reasons to incorporate SVT into the VTE family
| Risk/history . | Reasons . | Comments (references) . |
|---|---|---|
| Risk factors | 1. Not an entirely benign disease | DVT, PE, and fatality not rare (15,,,–19, 23, 24, 26) |
| 2. Both SVT and VTE associated with similar clinical hypercoagulability (eg, trauma, surgery, pregnancy, immobility, obesity, advancing age, malignancy) | 23, 25 | |
| 3. Incidence of thrombophilia enriched in both SVT and VTE patients | 18, 23,,–26 | |
| Natural history | 1. Coexistence of VTE at time of diagnosis of VTE | Averages ∼ 25% (17, 22,–24) |
| 2. Progression of SVT to VTE | Averages ∼ 10%-20% per year | |
| 3. Prior VTE a risk factor for future SVT | 21, 23, 24 | |
| 4. Prior SVT a risk factor for future VTE | 15, 23 | |
| 5. No current plausible putative theory that justifies segregation of (local) SVT apart, different, and unique from (systemic) VTE | 27, 28 |
| Risk/history . | Reasons . | Comments (references) . |
|---|---|---|
| Risk factors | 1. Not an entirely benign disease | DVT, PE, and fatality not rare (15,,,–19, 23, 24, 26) |
| 2. Both SVT and VTE associated with similar clinical hypercoagulability (eg, trauma, surgery, pregnancy, immobility, obesity, advancing age, malignancy) | 23, 25 | |
| 3. Incidence of thrombophilia enriched in both SVT and VTE patients | 18, 23,,–26 | |
| Natural history | 1. Coexistence of VTE at time of diagnosis of VTE | Averages ∼ 25% (17, 22,–24) |
| 2. Progression of SVT to VTE | Averages ∼ 10%-20% per year | |
| 3. Prior VTE a risk factor for future SVT | 21, 23, 24 | |
| 4. Prior SVT a risk factor for future VTE | 15, 23 | |
| 5. No current plausible putative theory that justifies segregation of (local) SVT apart, different, and unique from (systemic) VTE | 27, 28 |